Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

被引：0
|
作者：
Chia, Stephen
Neven, Patrick
Ciruelos, Eva M.
Lerebours, Florence
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Park, Yeon Hee
Juric, Dejan
Turner, Nicholas C.
Chattar, Yogesh
Patino, Heather
Akdere, Murat
Rugo, Hope S.
机构：
[1] Univ British Columbia, Vancouver, BC, Canada
[2] Univ Hosp, Leuven, Belgium
[3] Hosp 12 Octubre, Med Oncol Dept, Madrid, Spain
[4] PSL Res Univ, Inst Curie, St Cloud, France
[5] Hosp Virgen Rocio Sevilla, Seville, Spain
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] Hosp Clin Barcelona, Barcelona, Spain
[8] Samsung Med Ctr, Seoul, South Korea
[9] Massachusetts Gen Hosp, Boston, MA USA
[10] Royal Marsden NHS Fdn Trust, London, England
[11] Inst Canc Res, London, England
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Novartis Pharma AG, Basel, Switzerland
[15] Univ Calif San Francisco, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1078
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B
    Juric, Dejan
    Turner, Nicholas
    Loi, Sherene
    Andre, Fabrice
    Chia, Stephen K.
    Jhaveri, Komal
    Neven, Patrick
    Dent, Rebecca
    Ciruelos, Eva
    Joshi, Mukta
    Roux, Estelle
    Patino, Heather
    Akdere, Murat
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [3] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [4] Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
    Jhaveri, Komal L.
    Accordino, Melissa K.
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Schmid, Peter
    Saura, Cristina
    Turner, Nicholas C.
    Varga, Andrea
    Cheeti, Sravanthi
    Hilz, Stephanie
    Hutchinson, Katherine E.
    Jin, Yanling
    Royer-Joo, Stephanie
    Peters, Ubong
    Shankar, Noopur
    Schutzman, Jennifer L.
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)
  • [5] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve
    Ciruelos, E.
    Lerebours, F.
    Ruiz Borrego, M.
    Bachelot, T.
    Polikoff, J.
    Chia, S.
    Juric, D.
    Turner, N.
    Ridolfi, A.
    Sophos, N.
    Cooper, B.
    Thuerigen, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 141 - 141
  • [7] The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
    Li, Shuo
    Zhang, Qi-Li
    Guo, Rui-Jun
    OPEN MEDICINE, 2023, 18 (01):
  • [8] Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
    Maria Ciruelos, Eva
    Rugo, Hope S.
    Mayer, Ingrid A.
    Levy, Christelle
    Forget, Frederic
    Delgado Mingorance, Juan Ignacio
    Safra, Tamar
    Masuda, Norikazu
    Park, Yeon Hee
    Juric, Dejan
    Conte, Pierfranco
    Campone, Mario
    Loibl, Sibylle
    Iwata, Hiroji
    Zhou, Xiaolei
    Park, Jinhee
    Ridolfi, Antonia
    Lorenzo, Ines
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) : 2005 - +
  • [9] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [10] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
    Andre, F.
    Ciruelos, E. M.
    Juric, D.
    Loibl, S.
    Campone, M.
    Mayer, I. A.
    Rubovszky, G.
    Yamashita, T.
    Kaufman, B.
    Lu, Y-S
    Inoue, K.
    Papai, Z.
    Takahashi, M.
    Ghaznawi, F.
    Mills, D.
    Kaper, M.
    Miller, M.
    Conte, P. F.
    Iwata, H.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 208 - 217
12345